Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression

Therapeutic neoantigen cancer vaccines have limited clinical efficacy to date. Here, we identify a heterologous prime-boost vaccination strategy using a self-assembling peptide nanoparticle TLR-7/8 agonist (SNP) vaccine prime and a chimp adenovirus (ChAdOx1) vaccine boost that elicits potent CD8 T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramirez-Valdez, Ramiro A., Baharom, Faezzah, Khalilnezhad, Ahad, Fussell, Sloane C., Hermans, Dalton J., Schrager, Alexander M., Tobin, Kennedy K.S., Lynn, Geoffrey M., Khalilnezhad, Shabnam, Ginhoux, Florent, Van den Eynde, Benoit J., Leung, Carol Sze Ki, Ishizuka, Andrew S., Seder, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592466/
https://www.ncbi.nlm.nih.gov/pubmed/37279110
http://dx.doi.org/10.1016/j.celrep.2023.112599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592466/
https://www.ncbi.nlm.nih.gov/pubmed/37279110
http://dx.doi.org/10.1016/j.celrep.2023.112599

Ejemplares similares